What is it about?

As nucleotide analogues, thiopurines efficiently maintain control of immune mediated disease. The indication for a large use of thiopurines in the maintenance of inflammatory bowel disease (IBD) has come of age based on economic and medical issues: (1) IBD management costs fall to nadir during remission periods; (2) Patients’ quality of life is best when the IBD is in control. Shown to achieve mucosal healing, , thiopurines have now entered modern treat-to-target IBD algorithms.

Featured Image

Why is it important?

This paper provides definitive summary that thiopurines are still the drugs to beat in IBD in terms of: 1) Cost containment; 2) Mucosal Healing; 3) Reduction of colon neoplastic transformation.


I believe this paper might help those tending to believe that modern biological drugs can overshadow the indication for thiopurine in IBD: in fact, we hereby hold that as mucosal healing agents thiopurines carry more chances to behave as disease terminators that the biologics themselves, and in any case are crucial in co-administration regimes.

Giovanni Actis

Read the Original

This page is a summary of: A Concise History of Thiopurines for Inflammatory Bowel Disease: From Anecdotal Reporting to Treat-to-Target Algorithms, Reviews on Recent Clinical Trials, January 2019, Bentham Science Publishers, DOI: 10.2174/1574887113666180910120959.
You can read the full text:




The following have contributed to this page